CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy demonstrated safety in patients with multiple myeloma (MM) and central nervous system (CNS) involvement ...

An indigenously developed CAR T-cell gene therapy has achieved a 73% response rate for certain blood cancers in India. The ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...